The primary hyperoxalurias are diseases of overproduction of oxalate. The immediate precursor of oxalate is glyoxylate. Metabolism of hydroxyproline, derived from collagen turnover or the diet, appears to be a major source of glyoxylate, and a potential target for a therapeutic strategy of substrate depletion.
Th e paper by Knight et al. 1 in this issue of Kidney International has added more support to the possibility that hydroxyproline and its metabolites in the mitochondria make a major contribution to the production of glyoxylate. Glyoxylate is the immediate precursor of oxalate, a simple dicarboxylic acid that has no known functional role in animals and is toxic to most organisms. Animals cannot metabolize oxalate and do not normally store it. Rather, oxalate is excreted in urine. Th e primary hyperoxalurias (PH1 and PH2) are rare genetic diseases wherein oxalate is generated in amounts exceeding the body's ability to handle it, resulting in supersaturation in urine and crystallization forming calcium oxalate kidney stones. 2 PH1 is caused by a defi ciency of alanine:glyoxylate aminotransferase-1 (AGT1), and PH2 by a defi ciency of glyoxylate reductase (GR). Both PH1 and PH2 lead to excretion of abnormally high quantities of oxalate and development of calcium oxalate crystals and stones in the kidney. Th e primary site for oxalate production is the liver, although the toxic manifestations of oxalosis develop in the kidney and in other organs. PH1 eventually culminates in renal failure aft er several years. PH2 has a less severe course.
AGT1 is expressed mainly in the liver. Its subcellular location is normally peroxisomal in humans and other primates, mitochondrial in dogs and cats, and both peroxisomal and mitochondrial in rats and mice. Its function is to convert glyoxylate to glycine ( Figure 1 ). Expression of GR is highest in the liver, but it is also expressed in other tissues. GR is located in mitochondria and cytoplasm. Its function is to convert glyoxylate to glycolate. Both AGT1 and GR are main players in the removal of glyoxylate, preventing its conversion to oxalate. 2, 3 Treatment options for the hyperoxalurias are limited. A recent review 4 considers classic treatments as well as some new approaches. A subset of PH1 patients benefi ts from pyridoxine supplementation. Liver transplantation is an eff ective treatment, for PH1 especially, because the liver is the major site of expression of AGT1. It has not been used for PH2. Gene therapy approaches would require repopulation of the majority of hepatocytes, but this may not suffi ce for PH2 because of the expression of GR in more diverse tissues. Th e use of chemical chaperones to stabilize proteins with missense mutations, allowing them to evade intracellular quality control surveillance and achieve functional activity, is an area of interest in many human genetic diseases, including PH1. However, both PH1 and PH2 are genetically heterogeneous, and many mutations in both, especially PH2, are expected to yield no protein product. Th ere are also situations in which a protein product is produced but the mutation is manifested in ways other than loss of biological stability, such as a direct eff ect on catalysis. Substrate depletion is a therapeutic approach with general applicability independent of the specifi c genetic defect. Substrate depletion therapy has been investigated in conjunction with lysosomal storage disorders, but the concept applies here as well. Th e substrate in this case is glyoxylate, the immediate precursor of oxalate. Is it possible to control the production of glyoxylate when its normal clearance is blocked?
By necessity, in order to manipulate a metabolic pathway, one has to understand the regulation, interaction, and subcellular distribution of the reactions, be aware of alternate or secondary catalytic activities and side reactions, and recognize the sources of metabolites that feed the pathway. Th e focus falls mainly on glycolate oxidase (GO), GR, and AGT1 as the enzymes at the end of the pathway to oxalate and on glyoxylate as the precursor. Such studies have been complicated by diffi culties in measuring low levels of metabolites in cells, and lack of suitable cellular or animal models. 2, 5, 6 Th is has been further complicated by the diff erent compartmentalization of the components of the pathway in humans as compared with the animals that would normally be used as research models. 2 Human hepatoma cells (HepG2) have been used in several studies, 5, 7 as have rat hepatocytes. Although HepG2 cells provide a good model for some aspects of the pathway, there are diff erences in the peroxisomal membrane permeability compared with that of liver hepatocytes. Isolated mitochondria have been used to investigate the mitochondrial components of the pathway. 8 A promising model system developed by Benham et al. 6 uses Chinese hamster ovary cells stably transfected with all combinations of human GO, GR, and commentar y AGT1 genes. Chinese hamster ovary cells do not endogenously produce these enzymes. This system can be used to investigate the interaction of the enzyme reactions in a pathway where all three enzymes are functioning or where one (for example, AGT1 or GR) is defi cient. Subcellular localization of enzymes is appropriate. Th is system also provides a model where potential pharmacological agents can be tested.
Using data from these and other studies, the pathways to glyoxylate and oxalate can be outlined (Figure 1) . Th e major sites of production of endogenous glyoxylate are the peroxisomes and the mitochondria. Glycolate is the major precursor of glyoxylate. In the peroxisome, glyoxylate can be derived from glycine through the reaction of d-amino acid oxidase or, more signifi cantly, from imported glycolate by reaction with GO. Glyoxylate can also be imported into peroxisomes from the cytoplasm. Glyoxylate is normally removed by transamination with alanine and AGT1, producing pyruvate and glycine. Excess glyoxylate in peroxisomes is converted to oxalate by GO or is transported out to the cytoplasm, where it is converted to oxalate by lactate dehydrogenase. Th e former reaction is normally a minor role for GO 5 but may become signifi cant if AGT1 is defi cient.
Glyoxylate is also produced in mitochondria through metabolism of 4hydroxyproline (Hyp). Mitochondrial glyoxylate is converted to glycolate through the action of GR or to glycine by AGT2 (Figure 1 ). AGT2 is distinct from AGT1, and its location in human mitochondria has been recently confi rmed. 5 AGT1 is not normally found in mitochondria in humans. In the absence of GR, glyoxylate will be converted to oxalate.
Interest has developed recently in the possible role of Hyp as a signifi cant source of glyoxylate. Hyp is derived from meat and gelatin in the diet and from normal turnover of collagen. In a study of rats, Takayama et al. 9 demonstrated increased excretion of oxalate and glycolate in animals given Hyp. A prior injection with glucagon, demonstrated to induce mitochondrial AGT1, reduced the response to Hyp. Th e amount of Hyp given is admittedly severalfold higher than normal dietary levels, but the experiment indicated that oxalate can be formed in vivo from Hyp by metabolism to glyoxylate.
Studies with isolated mouse liver mitochondria 8 demonstrated that incubation with Hyp substantially increased glyoxylate production. Moreover, Khan et al. 10 described the use of Hyp to induce hyperoxaluria and nephrolithiasis in rats.
Knight et al. 1 present the most recent investigations into the role of metabolism of Hyp in glyoxylate and oxalate production in humans. Th e authors examined the eff ect of dietary Hyp from gelatin on normal human volunteers. Th ey showed that urinary oxalate and glycolate increased significantly after ingestion of large amounts of Hyp. Th ere was a proportional relationship between the amount of gelatin consumed and the urinary oxalate and glycolate produced. In addition, the results suggested that the kidney reabsorbs signifi cant quantities of Hyp and may contribute to the conversion of Hyp to glyoxylate through mitochondrial metabolism.
How important is the contribution of Hyp to glyoxylate? It was estimated that the normal breakdown of collagen contributes 20%-50% of excreted glycolate and up to 20% of urinary oxalate produced endogenously. 1, 8 In PH1, where AGT1 is absent, combined excretion of glycolate and oxalate may be in the range of 200-500 mg per day. 1, 8 Th e amount of Hyp degraded per day is 300-400 mg. Th is suggests that Hyp metabolism may be a major contributor to the glycolate→ glyoxylate→oxalate pathway. In PH2, excretion of oxalate and glycolate is lower, consistent with a functional AGT1 removing a portion of the glyoxylate. 1, 8 It seems reasonable to consider the path of degradation of Hyp as a suitable target for a substrate depletion strategy aimed at decreasing the generation of glyoxylate. It has been proposed 8 that Hyp analogues might be eff ective in blocking transport of Hyp into cells or mitochondria, or inhibiting normal metabolism of Hyp in mitochondria (Figure 1) . With the experimental model systems now available and enticing data such as those from Knight and colleagues, 1, 8 this will be a promising new direction for development of therapies for hyperoxaluria. 
